文献速递冠心病血脂与心血管预防

脂蛋白(a)与急性冠脉综合征后缺血事件复发风险:dal-Outcomes试验分析

Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2018-01-01

该研究为dal-Outcomes随机临床试验的巢式病例-队列分析,纳入969例发生主要心血管结局的病例和3170例无事件对照,测量急性冠脉综合征后基线脂蛋白(a)浓度。经16个基线变量调整后,脂蛋白(a)浓度每翻倍的心血管事件风险比为1.01(95%CI 0.96-1.06;

要点

  • 在近期急性冠脉综合征且接受他汀治疗的患者中,基线脂蛋白(a)水平与缺血性心血管事件复发风险无显著关联。
  • 结果提示针对降低脂蛋白(a)的治疗能否减少急性冠脉综合征后缺血事件风险尚需进一步研究。

核心结论

  • 对于近期发生急性冠脉综合征并接受他汀治疗的患者,脂蛋白(a)浓度与不良心血管结局无关。
  • 这些发现对特异性降低脂蛋白(a)水平能否降低急性冠脉综合征后缺血性心血管事件风险提出疑问。

研究设计与样本

  • 本研究为dal-Outcomes随机临床试验的巢式病例-队列分析,该试验在27个国家935个中心于2008年4月至2012年9月进行。
  • 纳入969例发生主要心血管结局的病例患者和3170例无事件对照患者,对照在病例事件发生时无事件且索引急性冠脉综合征类型匹配。
  • 脂蛋白(a)浓度采用免疫比浊法测定,数据分析于2016年6月8日至2017年4月21日进行。

主要发现

  • 基线脂蛋白(a)中位数(四分位距)为12.3(4.7-50.9)mg/dL。
  • 他汀类药物的使用率为97%(4030例)。

临床怎么用

  • 对于近期急性冠脉综合征且接受他汀治疗的患者,检测脂蛋白(a)水平可能无助于识别缺血性心血管事件复发高风险个体。
  • 不支持以降低脂蛋白(a)为目标来减少急性冠脉综合征后缺血性心血管事件风险的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It is uncertain whether lipoprotein(a) [Lp(a)], which is associated with incident cardiovascular disease, is an independent risk factor for recurrent cardiovascular events after acute coronary syndrome (ACS). OBJECTIVE: To determine the association of Lp(a) concentration measured after ACS with the subsequent risk of ischemic cardiovascular events. DESIGN, SETTING, AND PARTICIPANTS: This nested case-cohort analysis was performed as an ad hoc analysis of the dal-Outcomes randomized clinical trial. This trial compared dalcetrapib, the cholesteryl ester transfer protein inhibitor, with placebo in patients with recent ACS and was performed between April 2008 and September 2012 at 935 sites in 27 countries. There were 969 case patients who experienced a primary cardiovascular outcome, and there were 3170 control patients who were event free at the time of a case event and had the same type of index ACS (unstable angina or myocardial infarction) as that of the respective case patients. Concentration of Lp(a) was measured by immunoturbidimetric assay. Data analysis for this present study was conducted from June 8, 2016, to April 21, 2017. INTERVENTIONS: Patients were randomly assigned to receive treatment with dalcetrapib, 600 mg daily, or matching placebo, beginning 4 to 12 weeks after ACS. MAIN OUTCOMES AND MEASURES: Death due to coronary heart disease, a major nonfatal coronary event (myocardial infarction, hospitalization for unstable angina, or resuscitated cardiac arrest), or fatal or nonfatal ischemic stroke. RESULTS: The mean (SD) age was 63 (10) years for the 969 case patients and 60 (9) years for the 3170 control patients, and both cohorts were composed of predominantly male (770 case patients [79%] and 2558 control patients [81%]; P = .40) and white patients (858 case patients [89%] and 2825 control patients [89%]; P = .62). At baseline, the median (interquartile range) Lp(a) level was 12.3 (4.7-50.9) mg/dL. There was broad application of evidence-based secondary prevention strategies after ACS, including use of statins in 4030 patients (97%). The cumulative distribution of baseline Lp(a) levels did not differ between cases and controls at P = .16. Case-cohort regression analysis showed no association of baseline Lp(a) level with risk of cardiovascular events. For a doubling of Lp(a) concentration, the hazard ratio (case to control) was 1.01 (95% CI, 0.96-1.06; P = .66) after adjustment for 16 baseline variables, including assigned study treatment. CONCLUSIONS AND RELEVANCE: For patients with recent ACS who are treated with statins, Lp(a) concentration was not associated with adverse cardiovascular outcomes. These findings call into question whether treatment specifically targeted to reduce Lp(a) levels would thereby lower the risk for ischemic cardiovascular events after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00658515.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Schwartz GG, Ballantyne CM, Barter PJ, et al. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiol. 2018. PMID: 29071331. doi:10.1001/jamacardio.2017.3833

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。